LuxSit Pro is a light-generating reporter, while NovoBody proteins are next-generation antibody binders that recognize molecular targets. Both were designed using Monod Bio’s proprietary AI protein design platform. The agreement gives BPS Bioscience access to proprietary protein technologies for future research products and services. The companies expect to share details of specific offerings in a future product announcement.
“Monod’s technologies expand the possibilities for the innovative products and services we can bring to the drug discovery community,” said Henry Zhu, PhD, Chief Executive Officer of BPS Bioscience. “We’re excited to leverage these powerful protein technologies to develop next-generation solutions that support our customers’ research and development efforts.”